ViCardia Therapeutics, Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
ViCardia Therapeutics, a biopharmaceutical company, is entering Phase 2 with GP531, a potent, orally active therapy that treats mitochondrial dysfunction in heart failure. GP531 acts as an AMP-activated protein kinase (AMPK) agonist improving the bioenergetics in the myocardium and improving left ventricular ejection fraction.

GP531’s cardioprotective activity is both site- and event-specific.

GP531 is targeted at reversing the decline in the bioenergetic function of the mitochondria that often occurs with advancing age.

The Company’s research shows that GP531 enhances the OXPHO system located in the mitochondrial inner membrane and integrates the production of cellular energy in the form of ATP. The OXPHO system in mitochondria is responsible for the generation of the majority of cellular energy in the form of ATP.

ViCardia is led by a highly experienced management team and SAB with deep expertise in treating heart failure and conducting cardiovascular research.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
GP531
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
three
Speaker
photo
President & CEO
ViCardia Therapeutics, Inc.